## Elisa Piscianz

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1136517/publications.pdf

Version: 2024-02-01

567281 552781 44 768 15 26 citations h-index g-index papers 44 44 44 1599 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Type I interferon-mediated autoinflammation due to DNase II deficiency. Nature Communications, 2017, 8, 2176.	12.8	164
2	Regulatory T-Cell Function Is Impaired in Celiac Disease. Digestive Diseases and Sciences, 2009, 54, 1513-1519.	2.3	59
3	Altered germinal center reaction and abnormal B cell peripheral maturation in PI3KR1-mutated patients presenting with HIGM-like phenotype. Clinical Immunology, 2015, 159, 33-36.	3.2	51
4	The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases. International Journal of Molecular Sciences, 2018, 19, 4058.	4.1	46
5	The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation. Cytotherapy, 2010, 12, 154-160.	0.7	37
6	Lovastatinâ€induced apoptosis is modulated by geranylgeraniol in a neuroblastoma cell line. International Journal of Developmental Neuroscience, 2012, 30, 451-456.	1.6	33
7	Mevalonate Kinase Deficiency and Neuroinflammation: Balance between Apoptosis and Pyroptosis. International Journal of Molecular Sciences, 2013, 14, 23274-23288.	4.1	32
8	Curcumin Anti-Apoptotic Action in a Model of Intestinal Epithelial Inflammatory Damage. Nutrients, 2017, 9, 578.	4.1	27
9	Piccolipi $\tilde{A}^1$ , a multicenter birth cohort in Italy: protocol of the study. BMC Pediatrics, 2014, 14, 36.	1.7	26
10	Defect in mevalonate pathway induces pyroptosis in Raw 264.7 murine monocytes. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 882-888.	4.9	20
11	Theophylline as a precision therapy in a young girl with PIK3R1 immunodeficiency. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 2165-2167.	3.8	19
12	Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology. International Journal of Molecular Sciences, 2016, 17, 365.	4.1	18
13	Inhibition of mesenchymal stromal cells by pre-activated lymphocytes and their culture media. Stem Cell Research and Therapy, 2014, 5, 3.	5.5	16
14	Priming of the cGAS-STING-TBK1 Pathway Enhances LPS-Induced Release of Type I Interferons. Cells, 2021, 10, 785.	4.1	16
15	Fate of Lymphocytes after Withdrawal of Tofacitinib Treatment. PLoS ONE, 2014, 9, e85463.	2.5	16
16	An Easy and Reliable Strategy for Making Type I Interferon Signature Analysis Comparable among Research Centers. Diagnostics, 2019, 9, 113.	2.6	14
17	Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs. Current Medicinal Chemistry, 2018, 25, 2797-2810.	2.4	13
18	Lovastatin Dose-Dependently Potentiates the Pro-inflammatory Activity of Lipopolysaccharide Both In Vitro and In Vivo. Journal of Cardiovascular Translational Research, 2013, 6, 981-988.	2.4	12

#	Article	IF	Citations
19	MitoQ Is Able to Modulate Apoptosis and Inflammation. International Journal of Molecular Sciences, 2021, 22, 4753.	4.1	12
20	Microglia activation and interaction with neuronal cells in a biochemical model of mevalonate kinase deficiency. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 1048-1055.	4.9	11
21	Clinical Genetic Testing of Periodic Fever Syndromes. BioMed Research International, 2013, 2013, 1-8.	1.9	10
22	<i>In vivo</i> detection of polyomaviruses JCV and SV40 in mesenchymal stem cells from human umbilical cords. Pediatric Blood and Cancer, 2014, 61, 1347-1349.	1.5	10
23	Knockdown of MVK does not lead to changes in NALP3 expression or activation. Journal of Inflammation, 2015, 12, 7.	3.4	10
24	Neuronal Dysfunction Associated with Cholesterol Deregulation. International Journal of Molecular Sciences, 2018, 19, 1523.	4.1	9
25	Impact of Methylmercury and Other Heavy Metals Exposure on Neurocognitive Function in Children Aged 7 Years: Study Protocol of the Follow-up. Journal of Epidemiology, 2021, 31, 157-163.	2.4	9
26	Selective resistance to different glucocorticoids in severe autoimmune disorders. Clinical Immunology, 2010, 134, 313-319.	3.2	8
27	Differential action of 3-hydroxyanthranilic acid on viability and activation of stimulated lymphocytes. International Immunopharmacology, 2011, 11, 2242-2245.	3.8	8
28	Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway. International Journal of Molecular Sciences, 2016, 17, 47.	4.1	8
29	Immunomodulatory drugs in autoimmune lymphoproliferative syndrome (ALPS). Pediatric Blood and Cancer, 2012, 58, 310-310.	1.5	7
30	Altered pattern of tumor necrosis factor-alpha production in peripheral blood monocytes from Crohn's disease. World Journal of Gastroenterology, 2016, 22, 9117.	3.3	7
31	From Bone Marrow Transplantation to Cellular Therapies: Possible Therapeutic Strategies in Managing Autoimmune Disorders. Current Pharmaceutical Design, 2012, 18, 5776-5781.	1.9	5
32	To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies. International Journal of Molecular Sciences, 2015, 16, 21277-21293.	4.1	5
33	Clinical and Cytometric Study of Immune Involvement in a Heterogeneous Cohort of Subjects With RASopathies and mTORopathies. Frontiers in Pediatrics, 2021, 9, 703613.	1.9	5
34	Putative modifier genes in mevalonate kinase deficiency. Molecular Medicine Reports, 2016, 13, 3181-3189.	2.4	4
35	Is autophagy an elective strategy to protect neurons from dysregulated cholesterol metabolism?. Neural Regeneration Research, 2019, 14, 582.	3.0	4
36	The effect of clodronate on a mevalonate kinase deficiency cellular model. Inflammation Research, 2012, 61, 1363-1367.	4.0	3

3

#	Article	IF	CITATIONS
37	Hydroxychloroquine modulates immunological pathways activated by RNA:DNA hybrids in Aicardi–GoutiÔres syndrome patients carrying RNASEH2 mutations. Cellular and Molecular Immunology, 2021, 18, 1593-1595.	10.5	3
38	Clinical immunology Primary Immunodeficiency Diseases in two neighboring pediatric centers: registry data bring out a wide spectrum of diseases with complex clinical presentations. Central-European Journal of Immunology, 2012, 4, 365-370.	1.2	2
39	Temperature and Drug Treatments in Mevalonate Kinase Deficiency: An <i>Ex Vivo</i> Study. BioMed Research International, 2013, 2013, 1-8.	1.9	2
40	Familial hypogammaglobulinemia with high RTE and na $\tilde{A}$ ve T lymphocytes. Inflammation Research, 2019, 68, 901-904.	4.0	2
41	Immunity and Genetics at the Revolving Doors of Diagnostics in Primary Immunodeficiencies. Diagnostics, 2021, 11, 532.	2.6	2
42	Action of methotrexate and tofacitinib on directly stimulated and bystander-activated lymphocytes. Molecular Medicine Reports, 2016, 14, 574-582.	2.4	1
43	Mevalonate kinase deficiency: therapeutic targets, treatments, and outcomes. Expert Opinion on Orphan Drugs, 2017, 5, 515-524.	0.8	1
44	Tregs and Th17 lymphocytes in human DYRK1A haploinsufficiency. Immunology Letters, 2019, 214, 52-54.	2.5	1